Treating multidrug-resistant tuberculosis (MDR TB) with regimens that include a greater number of drugs may improve outcomes, and baseline drug susceptibility testing (DST) could identify drugs with the greatest likelihood of success, according to a paper published this week in PLOS Medicine. The prospective cohort study, conducted by Peter Cegielski of the Centers for Disease Control, Atlanta, Georgia, and colleagues, used information on regimen composition, baseline DST, and time to sputum conversion from 1,137 adults with MDR TB, from nine countries.
The World Health Organization (WHO) guidelines for the treatment of multidrug-resistant tuberculosis (MDR TB) recommend a regimen consisting of at least five potentially effective drugs. However, the researchers found that receiving an average of at least six potentially effective drugs per day was associated with a 36% (adjusted hazard ratio [aHR] 1.36, 95% CI 1.09-1.69) greater likelihood of responding to treatment (defined by time to initial sputum culture conversion) than receiving an average of at least five but fewer than six potentially effective drugs per day. Inclusion of more drugs to which baseline drug susceptibility testing (DST) results indicated susceptibility was associated with a 65% higher likelihood of sputum culture conversion per drug (aHR 1.65, 95% CI 1.48-1.84, per drug), and inclusion of pyrazinamide was associated with a doubling of the likelihood of sputum culture conversion (aHR 2.00, 95% CI 1.65-2.41). Surprisingly, including an additional drug to which baseline DST results indicated resistance was associated with a 33% higher likelihood of sputum culture conversion per drug (aHR 1.33, 95% CI 1.18-1.51, per drug). Inclusion of more drugs for which DST had not been performed was beneficial only if the regimen already contained a minimum of three likely effective drugs.
The authors caution that this is an observational study and cannot prove that increasing the number of drugs in treatment regimens or basing drug choice on DST results improves outcomes. Patients who received a particular treatment may have another shared characteristic that affected the disease outcome, other than those that the authors were able to adjust for in their analysis. The study is also limited by the use of initial sputum conversion and does not provide any information on risk of relapse, and that they were not able to assess the effects of individual drugs.
However, these results suggest changes to the current WHO guidelines for the treatment of MDR TB might be beneficial. The authors say: "... our analysis suggests that MDR TB regimens including more potentially effective drugs than the minimum of five currently recommended by WHO may encourage improved response to treatment in patients with MDR TB. In addition, rapid access to high quality DST results could facilitate the design of more effective individualized regimens."
This work was supported by the U.S. Agency for International Development, U.S. Centers for Disease Control and Prevention (CDC), U.S. National Institutes of Health's Division of Intramural Research of the National Institute for Allergy and Infectious Diseases, and the Korean Ministry of Health and Welfare. CDC Division of Tuberculosis Elimination led the study design, training for data collection and monitoring, data analysis, data interpretation, and writing of the report. Other sponsors had no roles in these activities. The views and opinions expressed in this article are those of the authors and do not necessarily represent an official position of the U.S. Centers for Disease Control and Prevention.
The authors have declared that no competing interests exist.
Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, et al. (2015) Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. PLoS Med 12(12): e1001932. doi:10.1371/journal.pmed.1001932
Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Tropical Disease Foundation, Manila, Philippines
Medical Research Council, Pretoria, South Africa
National Institute of Health, Lima, Peru
Partners In Health, Boston, Massachusetts, United States of America
Socios en Salud Sucursal, Lima, Peru
Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
Korean Institute of Tuberculosis, Seoul, Republic of Korea
Department of Disease Control, Ministry of Public Health, Bangkok, Thailand
Orel Oblast Tuberculosis Dispensary, Orel, Russian Federation
Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russian Federation
Taiwan Centers for Disease Control, Taipei, Taiwan
Tartu University Hospital, Tartu, Estonia
Central Tuberculosis Research Institute, Russian Academy of Medical Sciences, Moscow, Russian Federation
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:
Peter Cegielski firstname.lastname@example.org